Skip to search formSkip to main contentSkip to account menu

paritaprevir

Known as: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, (2R,6S,12Z,13aS,14aR,16aS)-N-(Cyclopropylsulfonyl)-6-{[(5-methyl-2-pyrazinyl)carbonyl]amino}-5,16-dioxo-2-(6-phenanthridinyloxy)-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamide, Veruprevir 
An orally bioavailable, synthetic acylsulfonamide inhibitor of the hepatitis C virus (HCV) protease complex comprised of non-structural protein 3 and… 
National Institutes of Health

Related topics

Related topics

8 relations

Broader (1)

ABT-450
Breast Cancer Resistance Protein Inhibitors [MoA]HCV NS3/4A Protease Inhibitors [MoA]Hepatitis CUGT1A1 Inhibitors [MoA]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
Highly Cited
2017
Highly Cited
2017
Direct‐acting antivirals in hepatitis C virus (HCV)‐infected and HCV/HIV‐coinfected patients: real‐life safety and efficacy
Clinical trials of all‐oral direct‐acting antivirals (DAAs) for chronic hepatitis C virus (HCV) infection reported high response… 
2017
2017
Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents
Highly effective direct antiviral agents (DAAs) for hepatitis C virus (HCV) were introduced recently. Their utilisation has been… 
Review
2016
Review
2016
Systematic review: current concepts and challenges for the direct‐acting antiviral era in hepatitis C cirrhosis
The burden of HCV cirrhosis is high and projected to increase significantly over the next decade. While interferon therapy is… 
Highly Cited
2016
Highly Cited
2016
The efficacy and safety of direct acting antiviral treatment and clinical significance of drug–drug interactions in elderly patients with chronic hepatitis C virus infection
Direct antiviral therapies for chronic hepatitis C virus (HCV) infection have expanded treatment options for neglected patient… 
Highly Cited
2016
Highly Cited
2016
How Generalizable Are the Results From Trials of Direct Antiviral Agents to People Coinfected With HIV/HCV in the Real World?
Trial results are used to support licensure, inform cost-effectiveness analyses, and guide clinical decision making. We found the… 
Review
2015
Review
2015
HCV targeting of patients with cirrhosis.
Highly Cited
2015
Highly Cited
2015
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised…
Highly Cited
2015
Highly Cited
2015
Resistance Analysis of Baseline and Treatment-Emergent Variants in Hepatitis C Virus Genotype 1 in the AVIATOR Study with Paritaprevir-Ritonavir, Ombitasvir, and Dasabuvir
ABSTRACT AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a protease inhibitor), ombitasvir (an NS5A… 
Highly Cited
2015
Highly Cited
2015
Natural history and treatment of Hepatitis C/HIV coinfection: is it time to change paradigms?
99 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)